---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016842"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:02:03.076823+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MindMed Q2 net loss $17.1M; Phase 2b LSD trial for GAD on track; reverse split 1-for-15

## Summary
- Q2 2022 net loss $17.1M vs $44.5M in Q2 2021; R&D expense $9.3M (up $1.2M YoY).
- Cash $105.7M as of June 30, 2022; runway through key clinical readouts into 2024.
- Phase 2b MM-120 (LSD) trial for GAD underway; first patient dosing expected Q3 2022, topline late 2023.
- Board approved 1-for-15 reverse share split effective Aug 26, 2022; split-adjusted trading Aug 29.
- Appointed Drs. Suzanne Bruhn and Roger Crystal as independent directors; Miri Halperin Wernli retired from board.

## SEC filing metadata
- accession: 0000950170-22-016842
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017022016842/0000950170-22-016842-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017022016842/mnmd-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016842
- JSON: https://secwatch.observer/filing/0000950170-22-016842.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016842.txt

## Key facts
- Executive change
  Miri Halperin Wernli resigned as Director at Definium Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On August 11, 2022, Miri Halperin Wernli, M.D. notified the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”) that she is resigning from the Board as of August 11, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000095017022016842/0000950170-22-016842-index.htm
- Executive change
  Suzanne Bruhn was appointed as Director at Definium Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On August 11, 2022, the Board appointed Suzanne Bruhn, Ph.D. to the Board, filling the vacancy left by the resignation of Dr. Halperin Wernli, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000095017022016842/0000950170-22-016842-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.